Table 1 Patients and transplant’s characteristics.
Characteristics | (n = 188) All patients | (n = 147) PCR-positive patients |
|---|---|---|
Age (years), median (range) | 50 (13.1–71) | 48.1 (13.1–71) |
Male, n (%) | 114 (60.6) | 84 (57.1) |
Baseline disease, n (%) | ||
Myeloid diseases | 117 (62.2) | 90 (61.2) |
Lymphoid diseases | 62 (33) | 50 (34) |
Others | 9 (4.8) | 7 (4.8) |
Recipient CMV IgG positive, n (%) | 146 (77.7) | 112 (76.2) |
Donor CMV IgG positive, n (%) | 124 (66) | 97 (67.4) |
Stem cell source, n (%) | ||
PB | 158 (84) | 122 (83) |
BM | 19 (10.1) | 15 (10.2) |
UC | 11 (5.9) | 10 (6.8) |
Type of donor, n (%) | ||
HLA-identical. related donor | 73 (38.8) | 56 (38.1) |
HLA-identical. unrelated donor | 52 (27.7) | 40 (27.2) |
Haploidentical family donor | 42 (22.3) | 33 (22.4) |
UCBT | 11 (5.9) | 10 (6.8) |
HLA missmatch related or unrelated donor | 10 (5.3) | 8 (5.4) |
Conditioning régimen, n (%) | ||
MAC | 90 (47.9) | 75 (51) |
GvHD prophylaxis, n (%) | ||
CsA-based regimen | 50 (26.6) | 40 (27.2) |
Post-Cy | 136 (72.3) | 104 (70.7) |
Others | 2 (1.1) | 3 (2.1) |
Prior GvHD, n (%) | ||
Acute | 92 (48.9) | 71 (48.2) |
Chronic | 127 (67.6) | 109 (74.1) |
Period of transplant, n (%) | ||
2018–2020 | 107 (56.9) | 80 (54.4) |
2015–2017 | 58 (30.8) | 46 (31.3) |
2012–2014 | 13 (6.9) | 11 (7.5) |
≤2011 | 10 (5.4) | 10 (6.8) |
Virus sampling periods, n (%) | ||
P1: Feb/2018–Sep/2018 | 145 (35.7) | 115 (38.3) |
P2: Feb/20219–Sep/2019 | 187 (46.1) | 145 (48.3) |
P3: Feb/2020–Sep/2020 | 74 (18.2) | 40 (13.3) |
Possible or proven CSRV LRTD, n (%)a | 52 (27.7) | 43 (29.3) |
IST during CSRV episode, n (%) | 124 (66) | 91 (61.9) |
Flu vaccination, n (%) | 64 (34) | 49 (33.3) |
Median days from allo-HSCT to CSRV screening, (range) | 373 (−4 to 5422) | 415 (−4 to 5422) |
Current status, n (%) | ||
Alive | 158 (83.6) | 124 (84.4) |
Exitus | 31 (16.5) | 23 (15.6) |
